Серцево-судинні ускладнення поліхіміотерапії множинної мієломи: сучасні напрями в діагностиці

Автор(и)

  • B. B. Samura Zaporizhzhia State Medical University, Ukraine,
  • M. O. Panasenko Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2409-2932.2020.1.198217

Ключові слова:

множинна мієлома, кардіоваскулярні події, хіміотерапія, діагностика, прогностичні фактори

Анотація

Мета роботи – пошук та узагальнення доказових даних щодо прогнозу та діагностики виникнення кардіоваскулярних подій у хворих на множинну мієлому.

Порушення серця при призначенні цитостатичних препаратів і моноклональних антитіл можуть бути лімітувальними факторами в лікуванні множинної мієломи. Побічні дії хіміотерапії включають гіпотензію, гіпертензію, аритмії, порушення проведення імпульсу, перикардит, тромбоемболічні ускладнення, серцеву недостатність, смерть.

Ризик розвитку кардіотоксичності збільшують деякі фактори, як-от ступінь експозиції препарату, вік, захворювання серця в анамнезі, артеріальна гіпертензія, комбінована терапія, попередні променева і хіміотерапія. Принциповим є виявлення ознак кардіоваскулярної токсичності до розвитку клінічних проявів пошкодження міокарда і судин. Залишається нез’ясованою роль маркерів у виявленні групи ризику несприятливих кардіоваскулярних подій.

Висновки. Рання діагностика і визначення прогностичних факторів кардіоваскулярної токсичності, які розвиваються після поліхіміотерапії онкогематологічних захворювань, є важливим і до кінця не з’ясованим завданням.

Посилання

Bazyka, D. A., Gudzenko, N. A., Dyagil, I. S., Babkina, N. G., Chumak, V. V., Bakhanova, E. V., Paramonov, V. V., & Romanenko A. Ye. (2013). Multiple myeloma among chornobyl accident clean, up workers – state and perspectives of analytical study. Problemy radiatsiinoi medytsyny ta radiobiolohii, (18), 169-172. [in Ukrainian].

Pazina, T. Yu., Korneva, E. A., Orlov, D. S., & Shamova, O. V. (2017). Mnozhestennaja mieloma: patogenez i novye podhody k terapii [Multiple myeloma: pathogenesis and new approaches to therapy]. Patogenez, 15(1), 4-10. [in Russian].

Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. Bmc Cancer, 14, Article 496. https://doi.org/10.1186/1471-2407-14-496

Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65

Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. H. (2018). Cardiovascular adverse events in multiple myeloma patients. Journal of Thoracic Disease, 10, S4296-S4305. https://doi.org/10.21037/jtd.2018.09.87

De Stefano, V., Za, T., & Rossi, E. (2014). Venous Thromboembolism in Multiple Myeloma. Seminars in Thrombosis and Hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793

Cornell, R. F., & Kassim, A. A. (2016). Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation, 51(4), 479-491. https://doi.org/10.1038/bmt.2015.307

Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs That May Cause or Exacerbate Heart Failure. A Scientific Statement from the American Heart Association. Circulation]. Praktychna anhiolohiia, (1), 52-65. [in Ukrainian].

Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma Relapse Involving the Heart and Presenting As Acute Cardiac Failure. Journal of Clinical Oncology, 32(18), E67-E68. https://doi.org/10.1200/jco.2012.47.6713

Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J., Neelapu, S. S., Ghia, P., … Dunleavy, K. (2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 101(5), 531-540. https://doi.org/10.3324/haematol.2015.139493

Lakomkin, V. L., Abramov, A. A., Gramovich, V. V., Vyborov, O. N., Lukoshkova, E. V., Ermishkin, V. V., & Kapelko, V. I. (2017). Dinamika formirovaniya sistolicheskoi disfunktsii serdtsa pri doksorubitsinovoi kardiomiopatii [The Time Course of Formation Of Systolic Dysfunction of the Heart in Doxorubicin Cardiomyopathy]. Kardiologiia, 57(1), 59-64. [in Russian]. https://doi.org/10.18565/cardio.2017.1.59-64

Akazawa, H. (2017). Cardiotoxicity of cancer chemotherapy – mechanisms and Therapeutic Approach. Gan to kagaku ryoho. Cancer & chemotherapy, 44(13), 2058-2063.

(2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist: Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Ch. 1 [The perspective of the European Society of Cardiologists. Cancer treatment and cardiovascular toxicity. Рart. 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].

Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European Heart Journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181

Postnikov, S. S., Gratianskaya, A. N., & Kostyleva, M. N. (2015). Lekarstvennye bolezni serdtsa i sosudov [Drug diseases of heart and blood vessels]. Pediatria, 94(2), 169-174. [in Russian].

Anokhin, V. N., Chushkin, M. I., & Kolganov, A. V. (2011). Antratsiklinovaya kardiomiopatiya [Anthracycline cardiomyopathy]. Terapevticheskiy arkhiv, 83(10), 72-76. [in Russian].

Amosova, K. M. (2016). Kardiomiopatii: suchasnyi pohliad na pytannia klasyfikatsii, etiolohii, diahnostyky ta dyferentsialnoi diahnostyky [Cardiomyopathies: modern view on the issues of classification, etiology, diagnosis and differential diagnosis. Part 1]. Sertse i sudyny, 2, 7-18. [in Ukrainian].

Ritchie, D. S., Seymour, J. F., Roberts, A. W., Szer, J., & Grigg, A. P. (2001). Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation, 28(1), 101-103. https://doi.org/10.1038/sj.bmt.1703098

Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, 5-6, 47-52. [in Ukrainian].

Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., … Prasad, S. K. (2013). Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. Jama-Journal of the American Medical Association, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192

Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Cardiotoxicity of chemotherapies. Presse Med, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014

Willis, M. S., & Patterson, C. (2013). Mechanisms of Disease Proteotoxicity and Cardiac Dysfunction - Alzheimer's Disease of the Heart? New England Journal of Medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180

Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., … Investigators, A. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352(24), 2487-2498. https://doi.org/10.1056/NEJMoa043445

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., … Investigators, A. (2015). Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., … Grp, T.-M. S. (2016). Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 374(17), 1621-1634. https://doi.org/10.1056/NEJMoa1516282

Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic non-communicable diseases: accent on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, (2), 26-32. [in Ukrainian].

Cardinale, D., Biasillo, G., Salvatici, M., Sandri, M. T., & Cipolla, C. M. (2017). Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Review of Molecular Diagnostics, 17(3), 245-256. https://doi.org/10.1080/14737159.2017.1283219

Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., … Yasui, Y. (2015). Individual Prediction of Heart Failure Among Childhood Cancer Survivors. Journal of Clinical Oncology, 33(5), 394-402. https://doi.org/10.1200/jco.2014.56.1373

Lipshultz, S. E., Adams, J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., … Council Nutr Phys Activity, M. (2013). Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association. Circulation, 128(17), 1927-1995. https://doi.org/10.1161/CIR.0b013e3182a88099

Solodiannikova, O. I., Golovko, T. S., Lavryk, G. V., & Shevchuk, L. A. (2012). Vozmozhnosti ekhokardiografii v otsenke kardiotoksichnosti khimioterapevticheskogo lecheniya bol'nykh onkologicheskogo profilya: sostoyanie problemy v literature, rezul'taty sobstvennykh issledovanii [Echocardiography capability in assessment of chemotherapy’s cardiotoxicity of oncologic patients (literature review, results of own examinations)]. Klinicheskaya onkologiya, (8), 144-150. [in Russian].

Fandeev, O. A., Vasechkin, S. S., Alekhin, M. N., Odintsov, S. V., Kallistov, V. E., & Sidorenko, B. A. (2011). Klinicheskoe znachenie kardiotoksichnosti antratsiklinov: sovremennye podkhody k diagnostike, profilaktike i lecheniyu [Clinical Value of Antracycline Toxicity: Modern Approaches to Diagnosis, Prevention, and Treatment]. Kardiologiia, 51(7), 40-46. [in Russian].

Chernov, V. I., Kravchuk, T. L., Zelchan, R. V., & Goldberg, V. E. (2015). Radionuklidnye metody issledovaniya v otsenke kardiotoksichnosti antratsiklina [Radionuclide Methods in the Assessment of Anthracycline-Induced Cardiotoxicity]. Kardiologiia, 55(7), 57-62. [in Russian].

Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J. S., Cleland, J. G. F., Pennell, D. J., & Christmas Study Steering Comm, I. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance - Are they interchangeable? European Heart Journal, 21(16), 1387-1396. https://doi.org/10.1053/euhj.2000.2011

Vogel-Claussen, J., Finn, J. P., Gomes, A. S., Hundley, G. W., Jerosch-Herold, M., Pearson, G., … Bluemke, D. A. (2006). Left ventricular papillary muscle mass: Relationship to left ventricular mass and volumes by magnetic resonance imaging. Journal of Computer Assisted Tomography, 30(3), 426-432. https://doi.org/10.1097/00004728-200605000-00013

Thavendiranathan, P., Walls, M., Giri, S., Verhaert, D., Rajagopalan, S., Moore, S., Simonetti, O. P., & Raman, S. V. (2012). Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 Mapping. Circulation-Cardiovascular Imaging, 5(1), 102-110. https://doi.org/10.1161/circimaging.111.967836

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192

Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popovic, Z. B., & Marwick, T. H. (2013). Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035

Samura, B. B., Kolesnyk, Yu. M., & Syvolap, V. V. (2014). Znachennia tsyrkuliuiuchoho halektynu-3 v prohnozuvanni kardiovaskuliarnykh podii u patsiientiv iz khronichnoiu limfotsytarnoiu leikemiieiu v remisii [Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission]. Zaporozhye medical journal, 2014, (6). 44-47. [in Ukrainain].

Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., … Scherrer-Crosbie, M. (2012). Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation-Cardiovascular Imaging, 5(5), 596-603. https://doi.org/10.1161/circimaging.112.973321

Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., … Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal-Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184

Vizіr, V. A., Popov, V. V., Kopitsa, N. P., & Voloshyna, I. N. (2011). Biomarkery pri serdechnoi nedostatochnosti - novye orientiry lechebnoi taktiki? [Biomarkers in heart failure – new objectives of therapeutic tactics?]. Sertse i sudyny, (2), 108-113. [in Russian].

Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prediction and evaluation of the effectiveness of heart failure therapy with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].

Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., … Cipolla, C. M. (2010). Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095

Specchia, G., Buquicchio, C., Pansini, N., Di Serio, F., Liso, V., Pastore, D., … Liso, A. (2005). Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. Journal of Laboratory and Clinical Medicine, 145(4), 212-220. https://doi.org/10.1016/j.lab.2005.02.003

Dorizzi, R. M., Caputo, M., Ferrari, A., Lippa, L., & Rizzotti, P. (2002). Comparison of serum and heparin-plasma samples in different generations of dimension troponin I assay. Clinical Chemistry, 48(12), 2294-2296.

Soker, M., & Kervancioglu, M. (2005). Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Medical Journal, 26(8), 1197-1202.

Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., … Yazaki, Y. (1998). Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal, 136(2), 362-363. https://doi.org/10.1053/hj.1998.v136.89908

Maries, L., & Manitiu, I. (2013). Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovascular Journal of Africa, 24(7), 286-289. https://doi.org/10.5830/cvja-2013-055

Yaris, N., Ceviz, N., Coskun, T., Akyuz, C., & Buyukpamukcu, M. (2002). Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. Journal of Experimental & Clinical Cancer Research, 21(2), 165-170.

Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International Journal of Molecular Sciences, 19(12), Article 3701. https://doi.org/10.3390/ijms19123701

US Food and Drug Administration. (2013, July 1). 510(k) Substantial Equivalence Determination Decision Summary; K093758. http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf

Syvolap, V. D., Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fi brosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, 2014, (5), 13-17. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2014.5.28742

Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F. T. (2003). Critical role of galectin-3 in phagocytosis by macrophages. Journal of Clinical Investigation, 112(3), 389-397. https://doi.org/10.1172/jci200317592

Krzeslak, A., & Lippinska, A. (2004). Galectin-3 as a multifunctional protein. Cellular & Molecular Biology Letters, 9(2), 305-328.

Samura, B. (2015). Prognosticheskaja rol galektina-3 u pacientov so mnozhestvennoj mielomoj v remissii [The prognostic role of galectin-3 in patients with multiple myeloma in remission]. Zaporozhye Medical Journal, (4), 11-16. [in Russian]. https://doi.org/10.14739/2310-1210.2015.4.50298

van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., … de Boer, R. A. (2013). Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH. Circulation-Heart Failure, 6(2), 219-226. https://doi.org/10.1161/circheartfailure.112.000129

Amin, H. Z., Amin, L. Z., & Wijaya, I. P. (2017). Galectin-3: A novel biomarker for the prognosis of heart failure. Clujul Medical, 90(2), 129-132. doi:10.15386/cjmed-751

Bentley, K., Franco, C. A., Philippides, A., Blanco, R., Dierkes, M., … Gerhardt, H. (2014). The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nature Cell Biology, 16(4), 309-321. https://doi.org/10.1038/ncb2926

Samura, B. (2016). Galectin-3 as a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian Medical News, 255, 56-61.

Samura, B. B. (2016). Predictive value of circulating N-Terminal Pro-Brain Natriuretic Protein and VE-Catherin in patients with regression of multiple myeloma. Biological Markers and Guided Therapy, 3(1), 125-132. http://dx.doi.org/10.12988/bmgt.2016.6413

##submission.downloads##

Номер

Розділ

Огляди